Drug Information

Drug General Information
Drug ID
D0M9QZ
Former ID
DCL000029
Drug Name
ABT-869
Synonyms
Linifanib; ABT 869; S1003_Selleck; AL-39324; RG-3635; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [528171], [528172], [541001]
Therapeutic Class
Anticancer Agents
Company
Abbott Laboratories
Structure
Download
2D MOL

3D MOL
Formula
C21H18FN5O
InChI
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
InChIKey
MPVGZUGXCQEXTM-UHFFFAOYSA-N
CAS Number
CAS 796967-16-4
PubChem Compound ID
11485656
PubChem Substance ID
16587270, 23620132, 42564545, 49689152, 50100086, 79067798, 99431596, 99431769, 103510213, 103904340, 121279556, 124490375, 124756926, 124772088, 125163733, 125334020, 126584078, 126636388, 126666451, 126728314, 131465097, 131477691, 134338740, 134964215, 135253632, 135685203, 135685207, 135685211, 135693528, 135723697, 136340278, 136368138, 136920256, 137262629, 137275904, 141225545, 143498888, 144115529, 152058517, 152234947, 152258823, 152344118, 160647674, 162011552, 162037378, 162118069, 162202645, 163124954, 164041875, 164761586
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 3 Target Info Modulator [528171], [549798]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
NetPath Pathway TNFalpha Signaling Pathway
Pathway Interaction Database VEGF and VEGFR signaling network
VEGFR3 signaling in lymphatic endothelium
Reactome VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Signaling by VEGF
References
Ref 528171Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
Ref 528172Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13.
Ref 541001(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5657).
Ref 528171Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
Ref 549798Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.